In the News | Charles River
   
 
 
   
   

Getting a Handle on Metabolic Disorders
Targets and Methods Vary, but the End-Goal Is the Same – More Effective Therapeutics
Genetic Engineering News - April 1, 2009

IBC’s “Targeting Metabolic Disorders” meeting, held late last month in Boston, was particularly timely given the new regulatory hurdles and higher standards for efficacy required for the next generation of metabolic drug products. Most of the presenters were confident that their research efforts would ultimately lead to the development of better metabolic therapeutics.

Representing Metabolex, Maria Wilson, Ph.D., senior scientist, and Charles McWherter, Ph.D., senior vp of research and preclinical development, discussed the company’s ongoing research. Dr. Wilson specifically reviewed her work with the GPR119 agonist MBX-2982, a drug candidate in Phase I development...Read the full article.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Jan 04 - New Cryopreservation and IVF Resou...
Dec 20 - ATNT Laboratories Now a Charles Ri...
Feb 17-Feb 18 - Aichi, Japan - Japan Society of Experimental Diabetes and Obesity (JSED...
Feb 08-Feb 10 - Brussels, Belgium - 6th Charles River European Short Course on Laborato...
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.